γ-Secretase inhibitors plus anti-BCMA chimeric antigen receptor T cells
- PMID: 37414007
- DOI: 10.1016/S1470-2045(23)00283-8
γ-Secretase inhibitors plus anti-BCMA chimeric antigen receptor T cells
Conflict of interest statement
AM reports consultancy for Bristol Myers Squibb and Jazz Pharmaceuticals, receiving honoraria from Takeda, and research funding from Jazz Pharmaceuticals. AS reports consultancy for Bristol Myers Squibb, Celenge, Gilead, Janssen, MSD, Novartis, Sanofi, Takeda, and GSK; contribution to a speakers bureau for Takeda, travel grants from Bristol Myers Squibb, Celenge, Janssen, Roche, Sanofi, and Takeda; and research support from Takeda and Bristol Myers Squibb.
Comment on
-
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.Lancet Oncol. 2023 Jul;24(7):811-822. doi: 10.1016/S1470-2045(23)00246-2. Lancet Oncol. 2023. PMID: 37414012 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials